Our piece European Urology co-led with Ziad Bakouny, MD, MSc is out! Here, we show via IMDC that pts with metastatic RCC (mRCC) undergoing upfront cytoreductive nephrectomy (CN) + 1L immunotherapy or targeted therapy LIVE LONGER than those who don't. A 🧵(1/5).
secure-web.cisco.com/1F-q37TXVHS-S8…

Congrats to our Chair, Dr. Kimryn Rathmell, on her election to National Academy of Medicine for “paving the way for new therapeutics” for basic science investigations of kidney cancer, and for the mentorship, recognition, and career advancement of physician-scientists.

bit.ly/3s8hEVD

I’m so intrigued and inspired by Nobel Laureate Carolyn Bertozzi that I just downloaded a review article on bioorthogonol chemistry (unusual for a medical oncologist). The Nobel Prize

Great talk by ari hakimi from Memorial Sloan Kettering Cancer Center. Really cool syngeneic mouse model with ccRCC-relevant mutations that can be used in immunocompetent mice. Great tool for studying immune TME. #KCRS22 #kidneycancer KidneyCAN

I’m pretty excited by this list of novel agents/treatment strategies in #kidneycancer presented by Rana McKay. We have never really directly targeted tumor cells in this disease. ADCs, novel targeted strategies, CAR-T, HIF inhibitors make this possible! #KCRS22 KidneyCAN

Team Kimryn Rathmell well represented at the #rocktherun #KCRS22 KidneyCAN 5K this morning. Channeling our inner Rocky in Philly on steps of art museum. Should have thought to invite Robert Hapke! Katy Beckermann Kathryn Hacker Gessner

Clinical trials session! Katy Beckermann Vanderbilt Hem / Onc discussing ciforadenant w ipi/nivo opening soon in #kidneycancer clinical trials consortium #KCRS22 KidneyCAN

#AnupamaReddy gave a great talk explaining the informatics behind our new RNAseq-based biomarker trial #OPTICRCC at #KCRS22 . Excited to launch this trial this! Use biology to choose 1st line therapy for ccRCC. Katy Beckermann Brian Rini, MD Vanderbilt-Ingram Cancer Center KidneyCAN #kidneycancer

7 degrees of Kimryn Rathmell at #KCRS22 ! Katy Beckermann rocked her oral presentation. Got to catch up Kathryn Hacker Gessner whom I met in Kim’s lab during UNC Hospitals residency. Had lunch with Robert Hapke who I comentored with Kim. Fun! Vanderbilt-Ingram Cancer Center VUMC Department of Medicine #kidneycancer

What a great quote. I like the Einstein quote he dropped in the interview too… “If at first the idea is not absurd, then there is no hope for it.” So we should strive to make our ideas more absurd and chase uncertainty.

Had a lot fun at the #uromigoslive #kidneycancer session! Congrats on a great event! @uromigos Brian Rini, MD Tom Powles Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center

Look forward to eventually opening the well designed, biomarker-based OPTIC trial for 1L mRCC Cleveland Clinic Moshe Ornstein MD Shilpa Gupta Christopher Wee, MD Brian Rini, MD Katy Beckermann Scott Haake, MD, PhD @UromigosLive #kidneycancer

Congrats to these #integrin scientists for winning #Lasker2022 . This community has advanced our understanding of this biology in wonderful ways. However, we are just scratching the surface in terms how these molecules can promote or suppress #cancer development. #ecmatrix

Sumanta Pal Toni Choueiri, MD James Brugarolas Eli Van Allen Scott Haake, MD, PhD ari hakimi Kimryn Rathmell Here's our first liquid biomarker that directly applies to doublet/triplet qx. Now integrated w/ctDNA in 3 clinical trials with Rana McKay Toni Choueiri, MD. Have to go from prognostic to predictive.
ascopubs.org/doi/10.1200/JC…

Updated table of the latest data for initial IO-based therapy in IMDC Int/Poor mRCC. See thread for discussion of imperfections and thoughts.